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Aims The ADVANCE study was designed to evaluate the safety and effectiveness of transcatheter aortic valve implant-
ation (TAVI) with a self-expanding bioprosthesis in real-world patients with symptomatic, severe aortic stenosis at
high surgical risk for valve replacement.
...................................................................................................................................................................................................
Methods
and results
Study participants were enrolled from 44 experienced centres in 12 countries. Patient eligibility, treatment ap-
proach, and choice of anaesthesia were determined by the local Heart Team. The study was 100% monitored, and
adverse events were adjudicated by an independent clinical events committee using Valve Academic Research
Consortium (VARC-1) criteria. There were 1015 patients enrolled with 996 attempted TAVI procedures. Mean
age was 81 years, and mean logistic EuroSCORE was 19.3 ± 12.3%. Five-year follow-up was available on 465
(46.7%) patients. At 5 years, the rate of all-cause mortality was 50.7% (95% confidence interval: 46.7%, 54.5%), and
the rate of major stroke was 5.4%. Haemodynamic measures remained consistent for paired patients with a mean
aortic valve gradient of 8.8 ± 4.4 mmHg (n= 198) and an effective orifice area of 1.7 ± 0.4 cm2 (n= 123). Aortic re-
gurgitation (AR) decreased over time and among paired patients dropped from 12.8% to 8.0% moderate AR at
5 years (n= 125). Of the 860 patients with echocardiographic data or a reintervention after 30 days, there were 22
(2.6%) patients meeting the VARC-2 criteria for valve dysfunction and 10 (1.2%) patients with a reintervention >30
days.
...................................................................................................................................................................................................
Conclusion Five-year results in real-world, elderly, high-risk patients undergoing TAVI with a self-expanding bioprosthesis pro-
vided evidence for continued valve durability with low rates of reinterventions and haemodynamic valve
dysfunction.
...................................................................................................................................................................................................
Trial registrationClinicalTrials.gov, NCT01074658.
                                                                                                                                                                                                                   
Keywords Transcatheter aortic valve implantation • Aortic valve durability • CoreValve • Aortic stenosis
* Corresponding author. Tel: þ49 173 672 0513, Fax: þ49 228 258007, Email: gerckensu@gmail.com
VC The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal (2017) 0, 1–10 CLINICAL RESEARCH
doi:10.1093/eurheartj/ehx295 TAVI
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Introduction
Short-term safety and efficacy of transcatheter aortic valve implant-
ation (TAVI) in symptomatic severe aortic stenosis patients at high
and extreme risk for surgery has been established in several pro-
spective clinical trials.1–4 More recently, TAVI has been shown to be
non-inferior to surgical valve replacement in symptomatic patients,
deemed intermediate risk for surgical intervention,5,6 and data from
one randomized, clinical trial have demonstrated similar safety and ef-
ficacy to surgery in low-risk patients with symptomatic severe aortic
stenosis.7 As adoption of TAVI expands into younger and lower risk
patients, longer term clinical outcomes and bioprosthetic valve dur-
ability are of increasing importance. Although clinical outcomes
through 3 to 5 years from multiple randomized clinical trials8–10 pro-
vide evidence for the safety of TAVI in higher risk patients, questions
regarding bioprosthetic valve durability remain a concern.11–13
The CoreValve ADVANCE study is a prospective, global multi-
centre observational clinical study that evaluated the self-expanding
CoreValve bioprosthesis for TAVI in a real-world population. Unlike
other large registries that may have under-reported adverse events,
the ADVANCE study was fully monitored, and all events were inde-
pendently adjudicated. Complete 5-year clinical and echocardio-
graphic data are now available. Additional post hoc analyses were
conducted to evaluate bioprosthetic valve durability through 5 years
and factors impacting mortality.
Methods
Patients and study design
Patient selection and design of the ADVANCE study have been
previously described.14 Briefly, ADVANCE is a global, prospective,
non-randomized, multicentre clinical study that enrolled real-world
patients with symptomatic, severe aortic valve stenosis suitable for
TAVI. Participants were enrolled at 44 centres from 12 countries; all
centres were required to have TAVI experience of at least 40 cases.
Each centre was also required to have a Heart Team comprised of
at least one TAVI-experienced interventional cardiologist and one
cardiothoracic surgeon to evaluate patient suitability for TAVI. The
ADVANCE study complied with the Declaration of Helsinki, with ap-
proval of the research protocol from all locally appointed ethics com-
mittees, and informed consent was obtained from all patients or their
legally authorized representative. Description of the CoreValve bio-
prosthesis and corresponding implant details have been presented
previously.15,16 CoreValve sizes of 26 and 29 mm were available dur-
ing the ADVANCE study to treat aortic valve annulus sizes from
20 mm to 27 mm. Each centre’s Heart Team determined the access
route (iliofemoral, direct aortic, or subclavian) and type of anaesthesia
(general or conscious sedation) for each patient. Follow-up visits
were scheduled at 30 days and then annually up to 5 years.
The primary endpoint of the ADVANCE study was major adverse car-
diac and cerebrovascular events at 30 days post-procedure, defined as a
composite of all-cause mortality, myocardial infarction, stroke, or reinter-
vention. Additional clinical endpoints included cardiovascular mortality,
vascular complications, major and minor stroke, and new pacemaker im-
plantation. The study was fully monitored, and adverse events were adju-
dicated by an independent clinical events committee comprised of
interventional cardiologists and cardiac surgeons using definitions from
Valve Academic Research Consortium (VARC-1).17 The committee
reviewed patient source data as well as assessments from an independent
neurologist to adjudicate all events.
Echocardiographic analysis
Echocardiographic data are reported by each investigative centre. Mean
gradient; effective orifice area (EOA); and total and paravalvular aortic re-
gurgitation (AR) data at baseline, discharge, 1 month, and annually to
5 years were analysed.
Prosthetic valve durability analysis
Prosthetic valve durability was assessed post hoc using echocardiographic
data and VARC-2 definitions.18 This analysis used the last available echo
post 30 days after implantation or the last echo before a reintervention
greater than 30 days post-procedure; only patients who had an echo in at
least one of these categories were included in the analysis. Surgical crite-
ria for aortic valve stenosis was defined as a greater than 50% increase of
mean gradient from 1 month to 5 years.19 VARC-2 criteria for aortic
valve stenosis was defined as: [(aortic valve mean gradient >_20 mmHg or
peak velocity >_3 m/s) and (EOA <_0.9 cm2 if body surface area is <1.6 or
<_1.1 cm2 if body surface area is >_1.6)] or moderate to severe total AR.18
Structural aortic valve deterioration, defined as valve dysfunction or de-
terioration, exclusive of infection or thrombosis, as determined by reop-
eration, autopsy, or clinical investigation was also collected during the
study. Specifically, this included changes intrinsic to the valve, such as
wear, fracture, calcification, leaflet tear, stent creep, or suture line disrup-
tion of components of a trial valve as site reported.
Statistical analysis
Continuous variables are reported as the mean ± standard deviation.
Categorical variables are reported as the number and percentage.
Clinical outcomes were calculated using Kaplan–Meier survival analysis,
and freedom from mortality curves were also generated using Kaplan–
Meier methods. The log-rank test was used to test for differences across
and between groups. For subjects without an event, the date of censoring
was the latest date of all follow-up visits (including study exit) and events
(including death). Predictors of mortality at 5 years were evaluated using
univariable and stepwise multivariable Cox regression models with an
entry P-value of 0.1 and a stay P-value of 0.05. Hazard ratios with two-
sided 95% confidence interval (CIs) were calculated. All tests were two
sided. All analyses were performed using SAS software (Cary, NC, USA),
version 9.2 or above.
Results
Patient and procedural characteristics
Baseline characteristics and procedural data for patients enrolled in
ADVANCE have been described previously.14 In brief, from March
2010 to July 2011, 1015 patients were enrolled and TAVI procedures
were attempted in 996 patients; 49.3% of patients were male, mean
age was 81 years, 80.0% were in NYHA Class III or IV, the mean STS
score was 6.4 ± 4.4%, and the mean logistic EuroSCORE was
19.3 ± 12.3%. Additional baseline characteristics can be found in
Supplementary material online, Table S1. For TAVI procedures, iliofe-
moral access was used in 88.4% of patients, subclavian access in 9.5%
and 2.1% had direct aortic access.14 Balloon valvuloplasty was per-
formed pre-procedure in 91.0% of patients and post-procedure in
23.6%.14 Five-year follow-up is available for 465 of 506 (91.9%) pa-
tients with attempted implant. There were 25 patient withdrawals,
2 U. Gerckens et al.
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.16 lost to follow-up and 490 patient deaths over 5 years (see
Supplementary material online, Figure S1).
Clinical outcomes and predictors of
mortality
Clinical outcomes at 1 and 5 years are shown in Table 1. At 5 years,
the rate of all-cause mortality was 50.7%, all-cause mortality or
major stroke was 51.8%, and cardiovascular mortality was 33.5%
(Figure 1A). The rate of stroke at 5 years was 10.2% with approxi-
mately half ajudicated as major stroke (5.4%) (Figure 1B).
The rate of new pacemaker implantation within 30 days post-TAVI
was 33.7% at 5 years but was not associated with an increase in mor-
tality (Figure 2A). When rates of freedom from all-cause mortality
were stratified by EuroSCORE the highest baseline EuroSCORE was
associated with the worst survival through 5 years (Figure 2B). The
impact of discharge AR is shown in Figure 2C. Moderate or severe AR
was associated with the lowest survival (45.2% at 5 years). There also
appears to be an impact of mild AR on mortality demonstrated only
after 2 years with a rate of 50.7% at 5 years. NYHA classification for
320 patients who were assessed at all time points of baseline,
1 month, and annually to 5 years indicated a gradual increase in Class
III symptoms during Years 3 through 5, but the majority of patients
remained Class I or II (80.9%) (see Supplementary material online,
Figure S2).
Multivariable predictors of mortality through 5 years are shown in
Figure 3; complete univariable and multivariable predictors are found
in Supplementary material online, Table S2. Multivariable predictors
of mortality were age, presence of peripheral vascular disease,
chronic obstructive lung disease, elevated serum creatinine, baseline
left ventricular ejection fraction <_50%, major bleeding and Stage 3
acute kidney injury. Higher baseline mean aortic valve gradient was
associated with lower mortality.
Echocardiographic measures
Echo compliance decreased over time with a follow-up rate of 67% at
Years 3 and 4 and 56% at 5 years. There were 125 patients with AR
measurements at baseline and all follow-up time points (discharge,
1 month, and annually to 5 years). At 5 years, 40.8% of these paired pa-
tients had no AR, compared with 21.6% at discharge. Degree of mod-
erate AR went from 12.8% at discharge to 8.0% at 5 years, and no
patients had severe AR from discharge to 5 years, inclusively (Figure
4A). Similarly, Figure 4B shows AR for all patients, including a category
for patients who were deceased or had a missed visit. Mean aortic valve
effective orifice area and mean gradient from baseline to 5 years are
shown in Figure 5. In patients with data at baseline and 5 years mean
gradient dropped from 45.3 ± 15.9 at baseline to 9.8 ± 4.4 mmHg at
discharge and 8.8 ± 4.4 mm Hg at 5 years (n= 198). Mean gradient
measurements for all available patients vs. patients with echocardio-
graphic follow-up at all time points are shown in Supplementary mater-
ial online, Table S3. Mean EOA for paired patients was 0.8 ± 0.5 at
baseline and 1.7 ± 0.4 cm2 at 5 years (n= 123).
Prosthetic valve durability
The incidence of structural valve deterioration was site reported as
0.9% at 5 years. Additional post hoc analysis on durability of the
CoreValve bioprosthesis was analysed in 860 patients (Table 2).
Mean follow-up time was 36.0 ± 21.1 months, and 267 patients had
follow-up through 5 years. There was a >50% increase in baseline
mean gradient in 9.3% of patients and the rate of valve dysfunction
per VARC-2 criteria was 2.6% (n= 22) at 5 years of follow-up. Two
of the 22 patients meeting criteria for aortic valve stenosis also had a
reintervention, 10 patients had a high mean gradient or peak velocity,
11 patients had moderate or severe AR, and 1 patient had a
high mean gradient and peak velocity plus moderate AR (Figure 6).
............................................ ...................................................
....................................................................................................................................................................................................................
Table 1 Clinical outcomes at 1 and 5 years (n5996)
1 Year 5 Years
% (n) 95% CI % (n) 95% CI
All-cause mortalitya 17.6 (174) [15.3, 20.1] 50.7 (489) [46.7%, 54.5%]
Cardiovascular mortality 11.6 (112) [9.7, 13.8] 33.5 (289) [29.3%, 37.8%]
All-cause mortality or major stroke 18.1 (179) [15.8, 20.6] 51.8 (501) [47.9%, 55.6%]
Strokea 4.4 (42) [3.2, 6.0] 10.2 (78) [7.2%, 13.7%]
Major stroke 2.1 (20) [1.3, 3.3] 5.4 (41) [3.3%, 8.2%]
Minor stroke 2.3 (22) [1.4, 3.5] 5.3 (40) [3.2%, 8.1%]
Transient ischaemic attack 1.7 (15) [0.9, 2.7] 2.6 (21) [1.2%, 4.8%]
Myocardial infarctiona 0.9 (8) [0.4, 1.8] 3.7 (27) [2.0, 6.1]
New pacemaker implantation 29.1 (284) [26.0, 32.3] 33.7 (312) [28.4, 39.0]
Emergent cardiac surgery or percutaneous reinterventiona 1.6 (15) [0.9, 2.6] 2.8 (23) [1.4, 5.0]
Acute kidney injury (all 3 stages) 6.6 (64) [5.0, 8.4] 10.1 (87) [7.1, 13.6]
Life-threatening or disabling bleeding 4.9 (48) [3.6, 6.5] 6.2 (57) [3.9, 9.2]
Structural valve deteriorationb 0.2 (2) [0.0, 0.8] 0.9 (6) [0.2, 2.5]
Major adverse cardiac and cerebrovascular events 21.0 (208) [18.5, 23.6] 55.8 (541) [51.9, 59.5]
Data presented as Kaplan–Meier estimates of outcomes in the attempted implant study cohort.
aComponents which comprise major adverse cardiac and cerebrovascular events.
bStructural valve deterioration includes trial valve dysfunction or deterioration, exclusive of infection or thrombosis, as determined by reoperation, autopsy, or clinical investiga-
tion. The term refers to changes intrinsic to the valve, such as wear, fracture, calcification, leaflet tear, stent creep, or suture line disruption of components of a trial valve.
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Ten (1.2%) patients had reinterventions after 30 days post-
procedure, where 4 procedures were surgical reinterventions and 6
were percutaneous. For these 10 reinterventions, 2 were caused by
prosthetic degeneration and subsequent aortic stenosis. Additional
details on the patients and their reintervention procedures are found
in Supplementary material online, Table S4.
Of the 996 patients, 1.8% (18 patients) were diagnosed with endo-
carditis, where 2 patients had 2 occurrences each of endocarditis.
Thirty-five per cent of cases were related to the prosthetic valve and
4 cases occurred within 6 months of the procedure. Three patients
died due to endocarditis.
Discussion
The CoreValve ADVANCE clinical study provides longer term
data on a large, real-world international population of TAVI
patients.14,20,21 The 5-year results from ADVANCE continue to dem-
onstrate the strong haemodynamic performance of the CoreValve
bioprosthesis, as well as low rates of stroke, AR, and a 5-year
mortality rate within the expected range for this elderly TAVI
population.
As the first TAVI procedure was performed just 15 years ago, to
date, there are only a few multicentre clinical studies with reported
results from 5 years of follow-up.9,13,22 All-cause mortality for pa-
tients in the CoreValve ADVANCE study was 50.7% (95% CI: 46.7%,
54.5%) at 5 years, similar to results described by Barbanti [55% (95%
CI: 49–60%)]13 and Duncan (54.5%).22 PARTNER 1, a randomized
controlled trial of TAVI vs. surgical implantation, reported all-cause
mortality of 67.8% at 5 years,9 higher than ADVANCE, potentially
due to differences in study design and baseline risk of enrolled pa-
tients (STS score of 10.7 ± 3.5% for PARTNER 1 vs. 6.4 ± 4.4% for
ADVANCE). Likewise, cardiovascular mortality was 33.5% at 5 years
in ADVANCE and 53.1% for PARTNER 1.9 Barbanti et al.13 reported
Figure 1 Kaplan–Meier time to event analyses for select clinical endpoints. (A) Freedom from all-cause mortality through 5 years; (B) Freedom
from all stroke, major stroke, minor stroke, and transient ischaemic attacks per VARC-1 definitions.16
4 U. Gerckens et al.
Figure 2 Kaplan–Meier time-to-event analyses for all-cause mortality stratified by: (A) the presence of an existing pacemaker prior to TAVI,
the need for a new pacemaker, and no pacemaker; (B) logistic EuroSCORE (<_10%, >10–20%, and >20%); (C) aortic regurgitation (none, mild, and
moderate or severe).
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Figure 3 Forest plot for multivariable analysis of predictors of all-cause mortality through 5 years.
Figure 4 Aortic regurgitation through 5 years: (A) for patients with available data at all follow-up time points and (B) for all patients accounting for
those missing or dead.
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cardiovascular mortality of 28% at 5 years in a large Italian registry,
similar to ADVANCE.
There are limited data on rate of stroke at 5 years post-TAVI. The
rate of stroke at 5 years in ADVANCE was 10.2%, similar to the rate
of 10.4% in PARTNER 1.9 The Italian registry reported a 5-year
stroke rate of 7.5%.13 A number of clinical studies have described an
early incidence of strokes post-TAVI, followed by lower rates of
stroke over time.13,23 Similarly, in ADVANCE, the stroke rate at 30
days post-TAVI was 3.0%, and increased at a much slower rate after
that to 5 years.
The observed continued improvement in AR over time for paired
patients followed through 5 years are confirming of the findings from
the US CoreValve Pivotal Trial8 and may be related to continued
valve frame expansion or tissue ingrowth over time.
An evaluation of surgical bioprosthetic valve explants suggests that
an increase in mean gradient of >50% over discharge may correlate
with valve thrombosis.19 A recent presentation further showed an as-
sociation between subclinical leaflet thrombosis and a higher rate of
transient ischemic attacks.24 There was no measure of valve throm-
bosis in ADVANCE; however, 9.3% of patients had a 50% or more in-
crease in mean gradient. Additional clinical studies are ongoing to
further assess the relationship between leaflet immobility, subclinical
thrombosis, and clinical outcomes.
In ADVANCE, we identify a low rate of reinterventions after 30
days that is consistent with reports from other studies. There were 2
cases (0.6%) with aortic valve reintervensions with the CoreValve
bioprosthesis in the Italian registry; both were valve-in-valve TAVI
procedures occurring between 4 and 5 years.13 Moreover, there
were 3 patients with prosthetic dysfunction who did not undergo
reintervention: 1 case of endocarditis, 1 case of asymptomatic valve
degeneration with severe AR and 1 case of worsening (moderate-to-
severe) paravalvular regurgitation. Three-year follow-up of the
CoreValve High-Risk US pivotal trial reported a reintervention rate
of 2.5% in patients receiving TAVI but noted that the majority of
these events occurred before 30 days.8 Although 22 patients in
ADVANCE met VARC-2 criteria for aortic stenosis, only 2 had
reinterventions. The low rate of reintervention and aortic valve sten-
osis assessed after 30 days provides reassuring data regarding the
durability of the self-expanding CoreValve through 5 years.
Figure 5 Haemodynamic measures from baseline through 5 years. Effective orifice area is shown in blue and mean gradient is shown in orange.
.................................................................................................
Table 2 Prosthetic valve durability
Characteristic n5 860
Mean follow-up (months) 36.0 ± 21.1
First and third quartile of follow-up time (months) [13.5, 59.3]
Reintervention after 30 days 10 (1.2%)
Surgical criteria for aortic valve stenosisa 80 (9.3%)
VARC-2b criteria for aortic valve stenosisc 22 (2.6%)
Reintervention after 30 days or VARC-2 criteria 30 (3.5%)
VARC, Valve Academic Research Consortium; AV, aortic valve; EOA, effective
orifice area; BSA, body surface area.
a>50% increase of mean gradient from 1 month to 5 years.
bThe analysis set included subjects with at least 1 echo post 30 day or reinterven-
tion >30 days; 267 patients had follow-up at 5 years.
cVARC-2 definition: (AV mean gradient >_20 mmHg or peak velocity >_3 m/s) and
(EOA <_0.9 cm2 if BSA <1.6 or <_ 1.1 cm2 if BSA >_1.6) or (>_moderate/severe total
aortic regurgitation).
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Predictors of mortality through 5 years were consistent with those
identified at 1 year.14 Peripheral vascular disease, elevated serum cre-
atinine, low ejection fraction, and acute kidney injury remained as
predictors and as expected, greater age is associated with a higher
risk for mortality through 5 years. When freedom from mortality was
stratified by degree of AR, we noted lower rates of survival for pa-
tients with moderate/severe and mild AR (detectable after 2 years) at
discharge, suggesting that AR may contribute to higher mortality
over time. The FRANCE-2 Registry, which enrolled over 3000 pa-
tients, found that moderate-to-severe post-procedural AR was the
strongest independent predictor of 1-year mortality.25 Patients who
received a new pacemaker within 30 days post-procedure had similar
5-year survival to patients with an existing pacemaker or no pace-
maker (log-rank P= 0.48). This is consistent with previous CoreValve
clinical studies that did not find any increase in mortality between pa-
tients with and without a new pacemaker.7,26
There are several limitations in our analysis. Echo visit compliance
at 5 years was only 56% and assessment of haemodynamic valve func-
tion overtime may underestimate the rate of valve dysfunction at
5 years. It is possible that patients who died during the study duration
without a recent echo may have had undiagnosed valve deterioration,
but the available echo data argue against a premature valve deterior-
ation. It is likely that some patients with AR died earlier in the study,
which affects the proportion of patients with mild or greater AR
at 5 years. Nevertheless, the paired echo data indicates that AR is
improving over time. In addition, echo measurements were site
reported, as there was no echo core lab adjudication for this study.
The 5-year results from the ADVANCE clinical study demon-
strated consistent low mean aortic valve gradients associated with
the self-expanding CoreValve and provide insights into longer term
clinical outcomes for ‘real-world’ TAVI patients. Analysis of biopros-
thetic valve durability through 5 years further demonstrated low
rates of reinterventions and haemodynamic valve dysfunction. As the
use of TAVI moves into lower risk, younger patients continued
follow-up will be essential to reassure physicians and patients of the
long-term safety of TAVI.
Supplementary material
Supplementary material is available at European Heart Journal online.
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